| Utility: Salts and crystals Filling date: 28 Sep 2025 Issue date: 13 Sep 2022 | 26 Sep 2018 | 13 Sep 2022 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 30 Aug 2022 | 20 Jul 2018 | 30 Aug 2022 |
| Utility: Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyr- rolo[1,2,3-de]quinoxaline Filling date: 28 Sep 2025 Issue date: 9 Aug 2022 | 7 Oct 2019 | 9 Aug 2022 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 5 Jul 2022 | 20 Jul 2018 | 5 Jul 2022 |
| Utility: Amorphous solid dispersions Filling date: 28 Sep 2025 Issue date: 17 May 2022 | 3 Oct 2017 | 17 May 2022 |
| Utility: Amorphous solid dispersions Filling date: 28 Sep 2025 Issue date: 26 Apr 2022 | 14 Dec 2018 | 26 Apr 2022 |
| Utility: Uses Filling date: 28 Sep 2025 Issue date: 5 Apr 2022 | 12 Sep 2017 | 5 Apr 2022 |
| Utility: Methods and compositions for sleep disorders and other disorders Filling date: 28 Sep 2025 Issue date: 7 Dec 2021 | 6 Feb 2020 | 7 Dec 2021 |
| Utility: 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrro- lo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms Filling date: 28 Sep 2025 Issue date: 23 Nov 2021 | 6 Mar 2019 | 23 Nov 2021 |
| Utility: Combinations of PDE1 inhibitors and NEP inhibitors Filling date: 28 Sep 2025 Issue date: 9 Nov 2021 | 19 Mar 2019 | 9 Nov 2021 |
| Utility: Compositions and methods Filling date: 28 Sep 2025 Issue date: 21 Sep 2021 | 27 Sep 2019 | 21 Sep 2021 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 24 Aug 2021 | 15 May 2020 | 24 Aug 2021 |
| Utility: Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof Filling date: 28 Sep 2025 Issue date: 20 Jul 2021 | 12 Dec 2019 | 20 Jul 2021 |
| Utility: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Filling date: 28 Sep 2025 Issue date: 6 Jul 2021 | 16 Jun 2020 | 6 Jul 2021 |
| Utility: Transmucosal methods for treating psychiatric and neurological conditions Filling date: 28 Sep 2025 Issue date: 6 Jul 2021 | 12 Jun 2020 | 6 Jul 2021 |
| Utility: Methods Filling date: 28 Sep 2025 Issue date: 6 Jul 2021 | 14 Apr 2013 | 6 Jul 2021 |
| Utility: Methods of treating bipolar disorder Filling date: 28 Sep 2025 Issue date: 8 Jun 2021 | 10 Jul 2019 | 8 Jun 2021 |
| Utility: Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7- H- pyrido[3',4':4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide Filling date: 28 Sep 2025 Issue date: 25 May 2021 | 28 Mar 2017 | 25 May 2021 |
| Utility: Pharmaceutical compositions for sustained or delayed release Filling date: 28 Sep 2025 Issue date: 30 Mar 2021 | 17 Jun 2019 | 30 Mar 2021 |
| Utility: Methods of treating schizophrenia and depression Filling date: 28 Sep 2025 Issue date: 30 Mar 2021 | 23 Apr 2019 | 30 Mar 2021 |
| Utility: Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders Filling date: 28 Sep 2025 Issue date: 30 Mar 2021 | 29 Dec 2017 | 30 Mar 2021 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 2 Feb 2021 | 29 Dec 2017 | 2 Feb 2021 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 26 Jan 2021 | 10 Feb 2020 | 26 Jan 2021 |
| Utility: Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)b- utan-1-one and methods of treating conditions of the central nervous system Filling date: 28 Sep 2025 Issue date: 24 Nov 2020 | 2 Oct 2019 | 24 Nov 2020 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 13 Oct 2020 | 14 Feb 2019 | 13 Oct 2020 |
| Utility: Transmucosal and subcutaneous compositions Filling date: 28 Sep 2025 Issue date: 21 Jul 2020 | 23 Mar 2018 | 21 Jul 2020 |
| Utility: Methods and compositions for sleep disorders and other disorders Filling date: 28 Sep 2025 Issue date: 7 Jul 2020 | 19 Oct 2018 | 7 Jul 2020 |
| Utility: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Filling date: 28 Sep 2025 Issue date: 30 Jun 2020 | 30 Aug 2019 | 30 Jun 2020 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 23 Jun 2020 | 24 Mar 2017 | 23 Jun 2020 |
| Utility: Uses Filling date: 28 Sep 2025 Issue date: 16 Jun 2020 | 13 Dec 2018 | 16 Jun 2020 |
| Utility: Compositions and methods Filling date: 28 Sep 2025 Issue date: 16 Jun 2020 | 28 Mar 2017 | 16 Jun 2020 |
| Utility: Salts and crystals of ITI-007 Filling date: 28 Sep 2025 Issue date: 19 May 2020 | 28 Mar 2017 | 19 May 2020 |
| Utility: Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrro- lo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof Filling date: 28 Sep 2025 Issue date: 24 Mar 2020 | 10 Jan 2019 | 24 Mar 2020 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 24 Mar 2020 | 3 Aug 2018 | 24 Mar 2020 |
| Utility: Organic compounds Filling date: 28 Sep 2025 Issue date: 28 Jan 2020 | 7 Sep 2018 | 28 Jan 2020 |
| Utility: Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]p- yrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl) butan-1-one for inhibiting serotonin reuptake transporter activity Filling date: 28 Sep 2025 Issue date: 12 Nov 2019 | 6 Aug 2018 | 12 Nov 2019 |
| Utility: Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-p- yrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof Filling date: 28 Sep 2025 Issue date: 5 Nov 2019 | 12 Jun 2019 | 5 Nov 2019 |
| Utility: Uses Filling date: 28 Sep 2025 Issue date: 3 Sep 2019 | 19 Sep 2017 | 3 Sep 2019 |
